A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bristol-Myers Squibb
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Men and women age 18 and older
6-36 months after kidney transplant receiving cyclosporine or tacrolimus
calculated GFR ≥35 and ≤75mL/min/1.73 m²
subjects must have completed 1 year in the IM103-010ST and remained on study treatment (Long Term Extension)
You may not be if
Significant infection
acute rejection within 3 months
prior graft loss due to rejection
pregnancy
positive crossmatch
Clareo Health | A Study of BMS-224818 (Belatacept) in Patients Who Have Undergone a Kidney Transplant and Are Currently on Stable Cyclosporine or Tacrolimus Regimen With or Without Corticosteroids
